相关实验视频

Updated: Mar 6, 2026

Evaluating In Vitro DNA Damage Using Comet Assay

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

通过抑制ALDH和表观遗传重编程,BET抑制增强了宫癌细胞对temozolomide的敏感性

Kemal Eker¹, Maryam Sabour Takanlou², Leila Sabour Takanlou²

¹Faculty of Medicine, Ege University, Izmir, Turkey.

Molecular biology reports

|March 4, 2026

概括

用JQ1抑制基因和外端 (BET) 抑制通过改变表观遗传调节和氧化应激来增强temozolomide (TMZ) 在宫癌细胞中的有效性. 这种组合疗法显示出改善治疗结果的潜力.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

宫癌是一种流行的妇科恶性瘤,具有显著的治疗耐药性.
甲基脱酶1 (ALDH1) 与宫癌中的化学抵抗和压力反应有关.
基蛋白和外端蛋白 (BET) 蛋白调节瘤进展中的转录和表观遗传程序.

研究的目的:

用JQ1研究BET抑制对宫癌中对temozolomide (TMZ) 的细胞反应的影响.
通过与TMZ结合的BET抑制来探索化学抵抗和表观遗传途径的调节.

主要方法:

用JQ1,TMZ或两者的组合对待HeLa细胞.
细胞活力,增殖和细胞亡被评估使用WST-1测定和流细胞计.
分析了氧化应激标志物 (MDA) 和表观遗传调节者的基因表达 (BET家族,ALDH异型).

主要成果:

联合JQ1和TMZ治疗比单个药物更有效地降低了细胞增殖和增加了细胞亡.
JQ1和组合治疗改变了氧化应激标志物 (降低了MDA水平).
基因表达分析揭示了染色质修饰酶的差异调节和BET和ALDH异型的协调下调.

结论:

由JQ1抑制BET会影响宫癌细胞对TMZ的敏感性.
组合疗法与改变的氧化应激和表观遗传调节者的转录重编程有关.
针对BET的策略显示了在宫癌中调节治疗反应的潜力,这需要进一步研究.

关键词:

细胞灭亡 (apoptosis) 是一种死亡的过程.宫癌是发生在宫癌的原因之一.表观遗传调节表观遗传调节 JQ1 一个问题氧化应激是一种氧化应激.泰莫佐洛米德 (Temozolomide) 是一种一种

更多相关视频

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...